NEJM January 8, 2026

This Week In Medicine · Jan 9, 2026 · 11m

A recent clinical study investigated the effectiveness of evolocumab, a PCSK9 inhibitor, in preventing major cardiovascular events for individuals who have never suffered a heart attack or stroke. Researchers conducted a massive trial involving over 12,000 participants with underlying conditions like diabetes or atherosclerosis to see if the medication could lower their initial risk. The results demonstrated that patients receiving the drug experienced significantly fewer life-threatening incidents and arterial procedures compared to those who took a placebo. Over a follow-up period of nearly…